Oncology Chromosome Analysis- BM/PB

Last Modified: 11/23/2022 12:38:06 PM


Medical Necessity Documentation:  
Client Notes: Order must include the reason for testing and a current CBC report and a stained peripheral blood slide
Patient Preparation: Anti-leukemic drug therapy may suppress cell division. The patient should not have received these drugs within 6 weeks of sample collection.
Specimen Requirements: 3.0 mL Bone Marrow in a Green Top Tube - Na Heparin 
Collection Instructions: Bone Marrow must contain 10% less mature myelocytes, pros or blasts

Clinical history/reason for referral is required with test order. Previous bone marrow transplant or therapy information, if applicable, should be provided with test order.

Minimum Volume: 2.0 mL Bone Marrow
Neonatal Volume: Infants: 2-3 mL (pediatric 3mL vacutainer)
Transport & Storage: Temperature/Stability: Ambient (Transport)

Specimen viability decreases during transit. Send specimen to testing laboratory for viability determination.
Rejection Criteria: Frozen
Reference Range: Reference Range Not Established
Critical Ranges:  
Test Comments:  
Methodology: Chromosome Analysis
Clinical Significance: Cytogenetic analysis used to determine chromosomal abnormalities important in diagnosis of hematologic malignancies, disease monitoring, and response to certain treatments
Documentation:  
Custom Panel: No

PRODUCTION SCHEDULE

Turn Around Time: 5 to 7 days
Sites Performed: GenPath Diagnostics
Other Testing Facility: to BioReference Laboratory
PHL Test Code: OCHRA
EPIC Test Code: LAB3233
Send Out Test Code: J948-1
Alternate Test Names: Cancer Cytogenetics Karyotype; Chrom-ONC BM/PB; Cytogenetics; Karyotype
Included Tests:  


CPT Coding: 88237, 88262, 88291

Go back to the top of the page.